Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 6:42 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 146 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Low Dose CT scan Clear all

Conditions: Prostate Cancer
Interventions: 99mTc-MIP-1404 Injection, Whole-Body Planar and pelvic SPECT/CT scan; Drug · Diagnostic Test
Lead sponsor: Molecular Insight Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 531 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 33
States / cities: Duarte, California • Los Angeles, California • San Francisco, California + 26 more

Conditions: Lung Carcinoma
Interventions: Liquid Biopsy, Low Dose Computed Tomography of the Chest, Survey Administration; Procedure · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 50 Years to 80 Years
Enrollment: 108 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: Sarcoidosis
Interventions: Fluorodeoxyglucose, Rubidium, FDG-PET/CT with Rb82 Myocardial Perfusion Imaging; Drug · Diagnostic Test
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Coronary Artery Disease, Ischemia
Interventions: Computed Tomography Angiography; Diagnostic Test
Lead sponsor: Johns Hopkins University; Other
Eligibility: 45 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Asthma
Interventions: N-acetylcysteine; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 80 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Renal Carcinoma, Renal Cell Carcinoma, Urothelial Carcinoma, Chromophobe Renal Cell Carcinoma, Translocation Renal Cell Carcinoma
Interventions: Cytokine Induced Memory-like Natural Killer (CIML NK) Cells, Interleukin-2 (IL-2); Biological · Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Pulmonary Arterial Hypertension
Interventions: 18F-FGLN PET Imaging, (18F)FPGLU; Diagnostic Test · Drug
Lead sponsor: Stephen Y. Chan; Other
Eligibility: 18 Years to 75 Years
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Diseases of Liver, Colon Carcinoma, Colorectal Carcinoma, Liver Metastases
Interventions: Computed Tomography Scan - 50% Dose Reduction, Computed Tomography Scan - 70% Dose Reduction, Deep Learning Image Reconstruction (DLIR); Diagnostic Test
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 90 Years
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Aortic Stenosis
Interventions: Not listed
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2014
U.S. locations: 2
States / cities: Plano, Texas

Conditions: Chest Pain
Interventions: low-dose imaging; Radiation
Lead sponsor: Spectrum Dynamics; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 2
States / cities: Los Angeles, California • Springfield, Oregon

Conditions: Coronary Artery Disease
Interventions: Placement of an aortic root pigtail catheter.; Procedure
Lead sponsor: Corewell Health East; Other
Eligibility: 20 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Prostate Cancer, Cancer of the Prostate
Interventions: Low-count quantitative single-photon emission computed tomography imaging; Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Male only
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Ann Arbor Stage I Small Lymphocytic Lymphoma, Ann Arbor Stage II Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia With Unmutated Immunoglobulin Heavy Chain Variable-Region Gene, Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable-Region Gene, Stage 0 Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Lenalidomide, Pneumococcal Polyvalent Vaccine; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 79 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Lung Cancer
Interventions: questionnaire administration, computed tomography, evaluation of cancer risk factors, study of high risk factors; Other · Procedure
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years to 120 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Glioma
Interventions: [11C]Acetate Brain Imaging; Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Mild Cognitive Impairment
Interventions: 2-(2-([18F]fluoro)pyridin-4-yl)-9H-pyrrolo[2,3-b:4,5-c']dipyridine; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 60 Years and older
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Kidney Stones
Interventions: low dose radiation abdomen/pelvis CT scan (stone protocol), Blood draw, 24 hour urine collection; Diagnostic Test · Procedure · Other
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Healthy Volunteers From Racial/Ethnic Minority Populations
Interventions: EXPLORER PET/CT; Device
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: VEGFR/PDGFR dual kinase inhibitor X-82, docetaxel, fluorine F 18 fluorothymidine, positron emission tomography/computed tomography, pharmacological study, laboratory biomarker analysis; Drug · Other · Procedure
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Hepatocellular Carcinoma Non-resectable
Interventions: Fluorine-18 fluorocholine; Combination Product
Lead sponsor: Queen's Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Lung Cancer, Lung Diseases
Interventions: Low Dose CT; Diagnostic Test
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 40 Years to 80 Years
Enrollment: 734 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cancer of Bone, Trauma, Aseptic Loosening of Orthopaedic Hardware
Interventions: Mg OSTEOCRETE as a bone void filler; Device
Lead sponsor: Santiago Lozano-Calderon; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Multiple Myeloma
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Chest Radiography, Computed Tomography, Daratumumab, Dexamethasone, Lenalidomide, Low Dose Computed Tomography of the Whole Body, Magnetic Resonance Imaging, Positron Emission Tomography, Venetoclax, X-Ray Imaging, Questionnaire Administration; Procedure · Biological · Drug + 1 more
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Femoracetabular Impingement
Interventions: Not listed
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 14 Years to 40 Years
Enrollment: 747 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 10
States / cities: Aurora, Colorado • Iowa City, Iowa • Boston, Massachusetts + 7 more

Search by objective public record fields.

Study to Evaluate 99mTc-MIP-1404 SPECT/CT Imaging in Men With Biopsy Proven Low-Grade Prostate Cancer

Feasibility of Cell-Free DNA Liquid Biopsy in Screening High-Risk Patients for Lung Cancer

Optimizing Acquisition Parameters and Interpretive Methods of FDG-PET/CT With Rb-82

Dynamic Computed Tomography Myocardial Perfusion Imaging for Detection of Coronary Artery Disease

Inpatient Clinical Trial of NAC

Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma

PET Image in PAH Patients

Lesion Detection Assessment in the Liver: Standard vs Low Radiation Dose Using Varied Post-Processing Techniques

Low-dose-contrast Cardiac Computed Tomography

Low Dose One-Day Tc99m Protocol With a High-Efficiency Cardiac Dedicated Gamma Camera For Detection of Coronary Disease

Coronary Artery and Coronary Artery Bypass Graft Imaging Using a Specialized Catheter and Computed Tomography

Low-Count Quantitative SPECT for Men Treated With Radium-223

Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

CT Scans in Screening for Lung Cancer in Current and Former Smokers

[11C]Acetate PET in Patients With Glioma

Linking Tau PET to Medial Temporal Lobe Subregions With High Resolution MRI

Donors With Nephrolithiasis at the Time of Transplant Evaluation (DONATE). Long Term Follow-up.

EXPLORER PET/CT: Evaluation of Healthy Individuals From Racial/Ethnic Minority Populations

VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Docetaxel in Treating Patients With Solid Tumors

Evaluation of Treatment Predictors Reflecting Beta-catenin Activation in Hepatocellular Carcinoma

Lung Cancer Risk and Early Detection in Firefighters

Mg OSTEOCRETE Post-Treatment Outcomes

MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma

Identification of Predictors for Clinical Outcomes in Femoroacetabular Impingement Surgery